Market Data
Market Cap₹2,252.5 Cr.
52W High₹647.5
Current Price₹367.75
52W Low₹293.1
Down from 52W High43.2 %
Face Value₹1
Performance
ROCE-0.46 %
ROE-0.85 %
EPS (TTM)₹0.38
EPS Prev Qtr₹0.08
EPS Last Year₹-2.27
EBITDA Qtr₹-2.23 Cr.
Book Value₹136
Financial Health
Debt/Equity0.03
Debt/Profit-2.65
Total Assets₹1,262.17 Cr.
Promoter Holding72.48 %
Earning Power-2.41 %
Valuation
Industry P/E33.81
Price to Book2.7
Price to Sales3.35
Key Metrics
__derived
1
Face Value
₹1
About Panacea Biotec Ltd
Healthcare · Pharmaceuticals
Panacea Biotec Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹1. Market cap ₹2,252.5 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 19.7% YoY, Profit fell 44.4% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 166.7 | 141.13 | 165.19 | 166.75 | 199.57 |
| ↳ QoQ Growth | - | -15.3% | +17.0% | +0.9% | +19.7% |
| Expenses | 176.27 | 167.26 | 161.9 | 172.06 | 201.8 |
| Operating Profit | -9.57 | -26.13 | 3.29 | -5.31 | -2.23 |
| OPM % | -5.74% | -18.51% | 1.99% | -3.18% | -1.12% |
| Other Income | 5.67 | 6.4 | 2.28 | 2.55 | 4.24 |
| Interest | 0.86 | 2.14 | 1.85 | 1.2 | 1.18 |
| Depreciation | 8.39 | 8.34 | 8.45 | 7.88 | 7.9 |
| EBITDA | -1.18 | -17.79 | 11.74 | 2.57 | 5.67 |
| EBITDA Margin % | -0.71% | -12.61% | 7.11% | 1.54% | 2.84% |
| Profit Before Tax | 6.56 | -19.17 | 6.49 | -1.25 | 3.57 |
| Tax % | 39.63% | 26.92% | 40.06% | 20% | 38.38% |
| Net Profit | 3.96 | -14.01 | 3.89 | -1 | 2.2 |
| ↳ QoQ Growth | - | -453.8% | +127.8% | -125.7% | +320.0% |
| EPS | 0.65 | -2.27 | 0.65 | 0.08 | 0.38 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 639.77 | 672.64 |
| Expenses | 677.49 | 703.02 |
| Operating Profit | -37.72 | -30.38 |
| OPM % | -5.9% | -4.52% |
| Other Income | 16.9 | 15.47 |
| Interest | 6.05 | 6.37 |
| Depreciation | 33.06 | 32.57 |
| Profit Before Tax | -7.37 | -10.36 |
| Tax % | 2.85% | 13.9% |
| Net Profit | -7.16 | -8.92 |
| EPS | -0.89 | -1.16 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
-9.33%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
-1.1%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 6.125 | 6.13 |
| Reserves | 807.007 | 828.71 |
| Borrowings | 22.21 | 23.66 |
| Other Liabilities | 454.4 | 403.67 |
| Total Liabilities | 1289.746 | 1262.17 |
| Fixed Assets | 585.653 | 568.77 |
| CWIP | 93.513 | 99.97 |
| Investments | 19.02 | 10.1 |
| Other Assets | 591.56 | 583.33 |
| Total Assets | 1289.746 | 1262.17 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -27.369 |
| Cash from Investing Activity | 64.984 |
| Cash from Financing Activity | -2.664 |
| Net Cash Flow | 34.951 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 706.59 |
| ROCE % | -3.05% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 72.48% | 72.48% | 72.48% | 72.48% |
| FIIs % | 1.06% | 1.36% | 1.6% | 2.31% |
| DIIs % | 1.81% | 1.85% | 1.96% | 2.25% |
| Public % | 17.69% | 17.49% | 16.81% | 15.54% |
| No. of Shareholders | 33,593 | 34,597 | 32,620 | 33,532 |
Major Shareholders (>1%)
- Dr. Rajesh JainPromoter and Promoter Group49.01%
- Mr. Sandeep JainPromoter and Promoter Group15.27%
- Mrs. Nirmala JainPromoter and Promoter Group4.10%
- First Lucre Partnership Co.Promoter and Promoter Group3.68%
As of 2026-06-30View all shareholders →